Literature DB >> 18240345

H pylori (CagA) and Epstein-Barr virus infection in gastric carcinomas: correlation with p53 mutation and c-Myc, Bcl-2 and Bax expression.

Valeska Portela Lima1, Marcos Antonio Pereira de Lima, Angela Rosa André, Márcia Valéria Pitombeira Ferreira, Marcos Aurélio Pessoa Barros, Sílvia Helena Barem Rabenhorst.   

Abstract

AIM: To investigate the interrelationship between H pylori and Epstein-Barr virus (EBV) infection in the gastric carcinogenesis having in focus the p53 mutation and the c-Myc, Bcl-2 and Bax expression.
METHODS: seventy-one gastric carcinoma tissues were assessed by polymerase chain reaction (PCR) for H pylori and in situ hybridization for EBV. c-Myc, Bcl-2 and Bax expression were detected by immunohistochemistry and single-stranded conformational polymorphism (SSCP) for p53 mutation.
RESULTS: The positivity rates for H pylori and EBV were 94.4% and 8.45%, respectively. The majority of the cases displayed only the H pylori presence. All EBV positive cases were also H pylori positive. None infectious agent was observed in 5.55% of the cases. The intestinal type tumor was more frequent in the co-infected and non-infected groups. The female predominated in the non-infected group showing statistical significance (70.4% vs 29.6%, P = 0.039). The Bcl-2 was only detected in the group exclusively infected by H pylori. However, c-Myc and Bax were detected in the three groups but with a low frequency in the co-infected group. Mutation of p53 was present in all groups, with the highest frequencies in the H pylori positive groups.
CONCLUSION: The frequency of H pylori infection in gastric carcinomas was high. The presented data indicated that gastric carcinogenesis has different pathways depending of the presence of the two investigated infectious agents, suggesting a possible involvement of H pylori with apoptotic process. The low expression of c-Myc and Bax in the EBV-positive groups suggests that EBV may inhibit the expression of these proteins. Nevertheless, p53 mutation shows to be a relevant alteration, independent of both infectious agents.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18240345      PMCID: PMC2687055          DOI: 10.3748/wjg.14.884

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  43 in total

1.  Epstein-Barr virus (EBV) infection and p53 protein expression in gastric carcinoma.

Authors:  Andrzej Szkaradkiewicz; Wacław Majewski; Marzena Wal; Mirosław Czyzak; Przemysław Majewski; Joanna Bierła; Alicja Kuch
Journal:  Virus Res       Date:  2006-01-18       Impact factor: 3.303

2.  [Clinical and molecular features of cardial gastric cancer associated to Epstein Barr virus].

Authors:  Alejandro Corvalán; Suminori Akiba; María Teresa Valenzuela; Miguel Angel Cumsille; Chihaya Koriyama; Jorge Argandoña; Claudia Backhouse; Matilde Bal; Fernando Mena; Mariana Palma; Yoshito Eizuru
Journal:  Rev Med Chil       Date:  2005-08-26       Impact factor: 0.553

3.  Telomerase activation by Epstein-Barr virus latent membrane protein 1 is associated with c-Myc expression in human nasopharyngeal epithelial cells.

Authors:  J Yang; X Deng; L Deng; H Gu; W Fan; Y Cao
Journal:  J Exp Clin Cancer Res       Date:  2004-09

4.  Low rate of apoptosis and overexpression of bcl-2 in Epstein-Barr virus-associated gastric carcinoma.

Authors:  T Kume; K Oshima; T Shinohara; H Takeo; Y Yamashita; T Shirakusa; M Kikuchi
Journal:  Histopathology       Date:  1999-06       Impact factor: 5.087

5.  Helicobacter pylori induces apoptosis in gastric mucosa through an upregulation of Bax expression in humans.

Authors:  P C Konturek; P Pierzchalski; S J Konturek; H Meixner; G Faller; T Kirchner; E G Hahn
Journal:  Scand J Gastroenterol       Date:  1999-04       Impact factor: 2.423

Review 6.  Helicobacter pylori and gastric cancer: a new paradigm for inflammation-associated epithelial cancers.

Authors:  JeanMarie Houghton; Timothy C Wang
Journal:  Gastroenterology       Date:  2005-05       Impact factor: 22.682

7.  Correlation of Epstein-Barr virus and its encoded proteins with Helicobacter pylori and expression of c-met and c-myc in gastric carcinoma.

Authors:  Bing Luo; Yun Wang; Xiao-Feng Wang; Yu Gao; Bao-Hua Huang; Peng Zhao
Journal:  World J Gastroenterol       Date:  2006-03-28       Impact factor: 5.742

8.  Epstein-Barr virus-associated gastric carcinoma in Kazakhstan.

Authors:  Gabit Alipov; Toshiyuki Nakayama; Masahiro Nakashima; Chun-Yang Wen; Daisuke Niino; Hisayoshi Kondo; Yuri Pruglo; Ichiro Sekine
Journal:  World J Gastroenterol       Date:  2005-01-07       Impact factor: 5.742

9.  Epstein-Barr virus infection and gastric carcinoma in São Paulo State, Brazil.

Authors:  L F Lopes; M M Bacchi; D Elgui-de-Oliveira; S G Zanati; M Alvarenga; C E Bacchi
Journal:  Braz J Med Biol Res       Date:  2004-10-26       Impact factor: 2.590

10.  Association between Epstein-Barr virus and Hodgkin's lymphoma in Belgium: a pathological and virological study.

Authors:  Mounir Trimèche; Christophe Bonnet; Sadok Korbi; Jacques Boniver; Laurence de Leval
Journal:  Leuk Lymphoma       Date:  2007-07
View more
  17 in total

1.  Differential expression of MYC in H. pylori-related intestinal and diffuse gastric tumors.

Authors:  Isabelle Joyce de Lima Silva-Fernandes; Markênia Kélia Santos Alves; Valeska Portela Lima; Marcos Antônio Pereira de Lima; Marcos Aurélio Pessoa Barros; Márcia Valéria Pitombeira Ferreira; Silvia Helena Barem Rabenhorst
Journal:  Virchows Arch       Date:  2011-05-03       Impact factor: 4.064

2.  Higher viral load of Epstein-Barr virus in gastric cancer compared with non-cancerous gastroduodenal tissues.

Authors:  Arghavan Zebardast; Maryam Pazhoohan; Azadeh Yazdani Cherati; Maryam Salehi; Saghar Saber Amoli; Yousef Yahyapour; Mohammad Ranaee; Javad Shokri Shirvani; Farzin Sadeghi
Journal:  Infez Med       Date:  2022-06-01

3.  Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location.

Authors:  Gwen Murphy; Ruth Pfeiffer; M Constanza Camargo; Charles S Rabkin
Journal:  Gastroenterology       Date:  2009-05-13       Impact factor: 22.682

4.  A case of gastric cancer with heterogeneous components of EB virus (+)/TP53 (+) and EB virus (-)/TP53 (-).

Authors:  Ikuo Matsuda; Kazuomi Kan; Sadayuki Doi; Yoshiyuki Motoki; Masayuki Onodera; Seiichi Hirota
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

Review 5.  MYC and gastric adenocarcinoma carcinogenesis.

Authors:  Danielle-Queiroz Calcagno; Mariana-Ferreira Leal; Paulo-Pimentel Assumpcao; Marilia-Arruda-Cardoso Smith; Rommel-Rodriguez Burbano
Journal:  World J Gastroenterol       Date:  2008-10-21       Impact factor: 5.742

Review 6.  Perspectives on new biomarkers in gastric cancer: diagnostic and prognostic applications.

Authors:  Danilo do Rosário Pinheiro; Wallax Augusto Silva Ferreira; Mariceli Baia Leão Barros; Mariana Diniz Araújo; Symara Rodrigues-Antunes; Bárbara do Nascimento Borges
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

7.  Analysis of p53, K-ras gene mutation & Helicobacter pylori infection in patients with gastric cancer & peptic ulcer disease at a tertiary care hospital in north India.

Authors:  Ashish Saxena; Sanket Kumar Shukla; Kashi Nath Prasad; Uday Chand Ghoshal
Journal:  Indian J Med Res       Date:  2012-10       Impact factor: 2.375

Review 8.  Polymicrobial infection and bacterium-mediated epigenetic modification of DNA tumor viruses contribute to pathogenesis.

Authors:  J M Doolittle; J Webster-Cyriaque
Journal:  MBio       Date:  2014-04-29       Impact factor: 7.867

Review 9.  Metabolic Control by DNA Tumor Virus-Encoded Proteins.

Authors:  Martin A Prusinkiewicz; Joe S Mymryk
Journal:  Pathogens       Date:  2021-05-06

10.  Lack of association between Bax promoter (-248G>A) single nucleotide polymorphism and susceptibility towards cancer: evidence from a meta-analysis.

Authors:  Sushil Kumar Sahu; Tathagata Choudhuri
Journal:  PLoS One       Date:  2013-10-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.